# A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

> **NCT01526057** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 220 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** PF-05280586
- **BIOLOGICAL:** MabThera
- **BIOLOGICAL:** Rituxan

## Key facts

- **NCT ID:** NCT01526057
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-20
- **Primary completion:** 2013-08-13
- **Final completion:** 2014-05-07
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2019-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01526057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01526057, "A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01526057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*